Breast and Ovarian Cancer Risks Due to Inherited Mutations in BRCA 1 and BRCA 2

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Not labeled

• Identifiers

  No identifiers available.

• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• No references are available for this paper.

• A transcription‐independent mechanism determines rapid periodic fluctuations of BRCA1 expression

  2023cites this paper
• Global trends in incidence, death, burden and risk factors of early-onset cancer from 1990 to 2019

  2023cites this paper
• No Cancer Occurrences in 10-year Follow-up after Prophylactic Nipple-sparing Mastectomy

  2023cites this paper
• A bibliometric study of the top 100 most cited papers on aging and cancer

  2023cites this paper
• The postulated innocuity of lifetime exposure to aluminium should be reappraised

  2023cites this paper
• A Highly Conserved Region in BRCA2 Suppresses the RAD51-Interaction Activity of BRC Repeats

  2023cites this paper
• Pancreatic cancer cluster region identified in BRCA2

  2023cites this paper
• “There should be one spot that you can go:” BRCA mutation carriers’ perspectives on cancer risk management and a hereditary cancer registry

  2023cites this paper
• Obesity promotes breast epithelium DNA damage in women carrying a germline mutation in BRCA1 or BRCA2

  2023cites this paper
• Barriers to hormone therapy following prophylactic bilateral salpingo-oophorectomy in BRCA1/2 mutation carriers

  2023cites this paper
• Modern interpretation of risk factors in breast cancer of women

  2022cites this paper
• Common founder BRCA2 pathogenic variants and breast cancer characteristics in Ethiopian Jews

  2022cites this paper
• Three Cases of False-positive Multiplex Ligation-dependent Probe Amplification of BRCA1

  2022cites this paper
• “It was a no-brainer”: A qualitative study of factors driving previvors’ decision-making when considering risk-reducing salpingectomy with delayed oophorectomy

  2022cites this paper
• Effects of diet education on empowerment for individuals who have an increased risk of developing breast or colon cancer: A pilot study

  2022cites this paper
• Ovarian cancer risk of Chinese women with BRCA1/2 germline pathogenic variants

  2022cites this paper
• Precise, Genotype-First Breast Cancer Prevention: Experience With Transferring Monogenic Findings From a Population Biobank to the Clinical Setting

  2022cites this paper
• Physical exercise during neoadjuvant chemotherapy for breast cancer as a mean to increase pathological complete response rates: Trial protocol of the randomized Neo-ACT trial

  2022cites this paper
• Fucoxanthinol Promotes Apoptosis in MCF-7 and MDA-MB-231 Cells by Attenuating Laminins–Integrins Axis

  2022cites this paper
• Evaluating the Effectiveness of a Telehealth Cancer Genetics Program: A BRCA Pilot Study

  2022cites this paper
• Incidence of other cancer diagnoses in women with breast cancer: a retrospective cohort study with 42,248 women

  2022cites this paper
• The impact of Angiopoietin-2 genetic polymorphisms on susceptibility for malignant breast neoplasms

  2022cites this paper
• Distinct roles of treatment schemes and BRCA2 on the restoration of homologous recombination DNA repair and PARP inhibitor resistance in ovarian cancer

  2022cites this paper
• Modification of BRCA1-associated breast cancer risk by HMMR overexpression

  2022cites this paper
• Recent Insights into PARP and Immuno-Checkpoint Inhibitors in Epithelial Ovarian Cancer

  2022cites this paper
• Progression-free survival and overall survival after BRCA1/2-associated epithelial ovarian cancer: A matched cohort study

  2022cites this paper
• Prognostic impact of germline BRCA1/2 pathogenic variants in breast cancer

  2022cites this paper
• The Breast Cancer Protooncogenes HER2, BRCA1 and BRCA2 and Their Regulation by the iNOS/NOS2 Axis

  2022cites this paper
• Sirtuin inhibition is synthetic lethal with BRCA1 or BRCA2 deficiency

  2021cites this paper
• Effects of obesity on breast aromatase expression and systemic metabo-inflammation in women with BRCA1 or BRCA2 mutations

  2021cites this paper
• Characteristics of Second Primary Breast Cancer after Ovarian Cancer: A Korea Central Cancer Registry retrospective study

  2021cites this paper
• A Novel Gene Prognostic Signature Based on Differential DNA Methylation in Breast Cancer

  2021cites this paper
• A rectovaginal septum mass in a BRCA1 positive patient years after risk reducing surgery: A case report

  2021cites this paper
• Baseline knowledge and receptiveness to genetic testing for hereditary breast and ovarian cancer syndromes in Chinese high-risk females

  2021cites this paper
• Decision aids for female BRCA mutation carriers: a scoping review protocol

  2021cites this paper
• Peutz–Jeghers Syndrome and the Role of Imaging: Pathophysiology, Diagnosis, and Associated Cancers

  2021cites this paper
• Risk Factor Analysis for Flap and Donor Site Related Complications in 1274 DIEP Flaps - Retrospective Single Center Study.

  2021cites this paper
• Patients with Biallelic BRCA1/2 Inactivation Respond to Olaparib Treatment Across Histologic Tumor Types

  2021cites this paper
• Germline RAD51B variants confer susceptibility to breast and ovarian cancers deficient in homologous recombination

  2021cites this paper
• Analysis of pathogenic variants in BRCA1 and BRCA2 genes using next-generation sequencing in women with triple negative breast cancer from South India

  2021cites this paper
• Experience in treating BRCA-associated breast cancer. The BRCA-history of a family

  2021cites this paper
• BRCA1 and BRCA2 Tumor Suppressor Function in Meiosis

  2021cites this paper
• Clinical use and mechanisms of resistance for PARP inhibitors in homologous recombination-deficient cancers

  2021cites this paper
• Comprehending the Proteomic Landscape of Ovarian Cancer: A Road to the Discovery of Disease Biomarkers

  2021cites this paper
• Physical activity and Mediterranean diet as potential modulators of osteoprotegerin and soluble RANKL in gBRCA1/2 mutation carriers: results of the lifestyle intervention pilot study LIBRE-1

  2021cites this paper
• A synergetic effect of BARD1 mutations on tumorigenesis

  2021cites this paper
• Research to reduce inequities in cancer risk services: Insights for remote genetic counseling in a pandemic and beyond

  2021cites this paper
• Can harmful lifestyle, obesity and weight changes increase the risk of breast cancer in BRCA 1 and BRCA 2 mutation carriers? A Mini review

  2021cites this paper
• Germline BRCA2 mutation pancreatic adenocarcinoma

  2020cites this paper
• BRCA1 and homologous recombination: implications from mouse embryonic development

  2020cites this paper
• Multigene Panel Germline Testing of 1333 Czech Patients with Ovarian Cancer

  2020cites this paper
• Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in and families: high cancer incidence at older age

  2020cites this paper
• Comparative efficacy, safety, and acceptability of single-agent poly (ADP-ribose) polymerase (PARP) inhibitors in BRCA-mutated HER2-negative metastatic or advanced breast cancer: a network meta-analysis

  2020cites this paper
• Germline mutations of multiple breast cancer-related genes are differentially associated with triple-negative breast cancers and prognostic factors

  2020cites this paper
• Genetic factors, adherence to healthy lifestyle behavior, and risk of invasive breast cancer among women in the UK Biobank.

  2020cites this paper
• Circulating tumor cells and breast cancer-specific mutations in primary breast cancer.

  2020cites this paper
• BRCA2 gene mutation and prostate cancer risk

  2020cites this paper
• Promises and perils of using genetic tests to predict risk of disease

  2020cites this paper
• Cell-cycle arrest and senescence in TP53-wild type renal carcinoma by enhancer RNA-P53-bound enhancer regions 2 (p53BER2) in a p53-dependent pathway

  2020cites this paper
• Double Heterozygosity in the BRCA1/2 Genes in a Turkish Patient with Bilateral Breast Cancer: A Case Report

  2020cites this paper
• “Response to the letter to the editor “Concerns regarding the potentially causal role of FANCA heterozygous variants in human primary ovarian insufficiency””

  2020cites this paper
• Genomic Instability Is an Early Event in Aluminium-Induced Tumorigenesis

  2020cites this paper
• Ernährung und körperliche Aktivität – Bedeutung für Prävention, Prognose und Therapie gynäkologischer Tumorerkrankungen

  2020cites this paper
• PGPM_A_233485 227..238

  2020cites this paper
• Identification of profiles of volatile organic compounds in exhaled breath by means of an electronic nose as a proposal for a screening method for breast cancer: a case-control study

  2020cites this paper
• Comparison of Patient Susceptibility Genes Across Breast Cancer: Implications for Prognosis and Therapeutic Outcomes

  2020cites this paper
• Epigenetic Regulation and Dietary Control of Triple Negative Breast Cancer

  2020cites this paper
• The DIEP Flap as Well-established Method of Choice for Autologous Breast Reconstruction with a Low Complication Rate – Retrospective Single-centre 10-Year Experience

  2020cites this paper
• Hereditary breast and ovarian cancer (HBOC): review of its molecular characteristics, screening, treatment, and prognosis

  2020cites this paper
• Increased Cancer Risk in Families with Pediatric Cancer Is Associated with Gender, Age, Diagnosis, and Degree of Relation to the Child

  2020cites this paper
• Discrepancies in Genetic Testing Procedures of BRCA1/2 Mutations: A National Survey Across China

  2020cites this paper
• How to manage BRCA mutation carriers?

  2020cites this paper
• Clinicoepidemilogical Correlation of BRCA 1 and 2 Mutations in Carcinoma Ovary - an Indian Perspective

  2019cites this paper
• PARP Inhibitors: Extending Benefit Beyond BRCA-Mutant Cancers

  2019cites this paper
• Synergistic lethality between BRCA1 and H3K9me2 loss reflects satellite derepression

  2019cites this paper
• Overview of the genetic basis toward early detection of breast cancer

  2019cites this paper
• Current Concepts in Role of Bilateral Salpingo-Oophorectomy in Non-Hereditary Metastatic Carcinoma of Breast: Review Article

  2019cites this paper
• Network-based microsynteny analysis identifies major differences and genomic outliers in mammalian and angiosperm genomes

  2019cites this paper
• A Pragmatic Testing-Eligibility Framework for Population Mutation Screening: The Example of BRCA1/2

  2019cites this paper
• Edinburgh Research Explorer Assessment of interactions between 205 breast cancer susceptibility loci and 13 established risk factors in relation to breast cancer risk in the Breast Cancer Association Consortium

  2019cites this paper
• DNA damage responses in ageing

  2019cites this paper
• Edinburgh Research Explorer Assessment of interactions between 205 breast cancer susceptibility loci and 13 established risk factors in relation to breast cancer risk in the Breast Cancer Association Consortium

  2019cites this paper
• Frozen Section Diagnosis of Ovarian Epithelial Tumors: Diagnostic Pearls and Pitfalls.

  2019cites this paper
• Updates in Genetic Testing Guidelines for Breast Cancer Susceptibility Genes: a Change in the Paradigm

  2019cites this paper
• Principles of diagnosis of ovarian neoplasms — minimization of errors

  2019cites this paper
• BRCA1/BRCA2 Pathogenic Variant Breast Cancer: Treatment and Prevention Strategies

  2019cites this paper
• OP-IJEJ190194 1..15

  2019cites this paper
• Mexican BRCA1 founder mutation: Shortening the gap in genetic assessment for hereditary breast and ovarian cancer patients

  2019cites this paper
• Contraception options for patients with known hereditary risk for ovarian cancer.

  2019cites this paper
• Assessment of interactions between 205 breast cancer susceptibility loci and 13 established risk factors in relation to breast cancer risk, in the Breast Cancer Association Consortium

  2019cites this paper
• Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers

  2019cites this paper
• Neoantigens and genome instability: impact on immunogenomic phenotypes and immunotherapy response

  2019cites this paper
• Novel Germline Mutations of BRCA1 and BRCA2 in Korean Familial Breast Cancer Patients

  2019cites this paper
• Endocrine therapy resistance: new insights.

  2019cites this paper
• PARP inhibitors in breast cancer: Bringing synthetic lethality to the bedside

  2018cites this paper
• Classification of large DNA methylation datasets for identifying cancer drivers

  2018cites this paper
• Management guidelines for BRCA positive women in South Africa and other limited resource settings

  2018cites this paper
• Single Nucleotide Polymorphisms: Identification and Association with Breast Cancer Using Biocomputing Approach

  2018cites this paper
• Germline BRCA1 and BRCA2 deleterious mutations and variants of unknown clinical significance associated with breast/ovarian cancer: a report from North India

  2018cites this paper
• Ataxia-telangiectasia gene (ATM) mutation heterozygosity in breast cancer: a narrative review.

  2018cites this paper